Adamas Pharmaceuticals is part of the healthcare sector and drug manufacturers industry. The company CEO is Gregory T. Went. Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company has developed and got approved the drug GOCOVRI.
Previous Intraday Performance:
The ADMS shares had a previous change of -1.19% which opened at 5.10 and closed at 4.99. It moved to an intraday high of 5.15 and a low of 4.93.
SeekingAlpha: Adamas Pharmaceuticals: Was It Overrated?
Historical Performance:
Over the last five trading days, ADMS shares returned -8.61% and in the past 30 trading days it returned -22.52%. Over three months, it changed -55.60%. In one year it has changed -83.85% and within that year its 52 week high was 29.49 and its 52 week low was 4.93. ADMS stock is 1.22% above its 52 week low.
Our calculations result in a 200 day moving average of 12.23 and a 50 day moving average of 6.51. Right now, ADMS stock is trading -59.21% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Adamas Pharmaceuticals: Was It Overrated?
Liquidity:
The company has a market cap of $137.4m with 27.5m shares outstanding and a float of 26.9m shares. Trading volume was 488,018 shares and has experienced an average volume of 399,578 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Adamas Pharmaceuticals was -4.88 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -1.13.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -1.08 |
|---|---|---|
| 4th | Qtr 2018 | -1.06 |
| 3rd | Qtr 2018 | -1.22 |
| 2nd | Qtr 2018 | -1.26 |
| 1st | Qtr 2018 | -1.35 |
Base on our calculations, the intrinsic value per share is 24.75, which means it might be undervalued and has a margin of safety of 79.84%.
The long-term trend of the EPS is a vital number as it helps understand the future potential of Adamas Pharmaceuticals; the EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been 1175.00% over the last twelve months.
Indicators Also to Watch:
The beta was calculated to be 1.46.
SeekingAlpha: Advanced Emissions Solutions Inc. (ADES) CEO Heath Sampson on Q1 2019 Results – Earnings Call Transcript
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -115.10%, return on assets is -50.78%, price-to-sales is 3.22 and price-to-book is 2.15.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
4 : Financial Safety Result
0 : Past Performance Result
3 : Valuation Result
0 : Dividend Safety Result
3 : Overall Result
Related Tags: Adamas Pharmaceuticals, ADMS, Drug Manufacturers, Healthcare
